Loading stock data…
$1.52-0.08 (-5.00%)
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.52 with a market capitalization of $36M. Wall Street consensus targets $4.00 (4 analysts), implying a +163.2% move over the next 12 months. The stock is currently 12% below its 52-week high of $1.72, remaining 35.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $35.00M | $0 | $0↓ | $90,000 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | $27.57M↑ | -$5.90M↑ | -$6.41M↓ | -$5.69M↑ | -$7.50M |
| Net Income | $27.90M↑ | -$5.52M↑ | -$5.94M↓ | -$5.13M↑ | -$6.88M |
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeut...